In pharmaceutical branding, creativity may spark the idea — but regulatory safety determines whether a name can ever reach the market. And with global agencies tightening linguistic, structural, and similarity requirements, name safety has become one of the most critical (and complex) stages of the naming process.

Enter MOSAIQTM ™.

As part of Brandsymbol’s commitment to building a smarter, faster, and safer naming ecosystem, MOSAIQ^TM  is redefining how regulatory insight integrates with creativity. Instead of treating safety as an end-stage checkpoint, MOSAIQ^TM  brings regulatory intelligence upstream — making compliance a collaborative, real-time component of ideation.

The result: safer lists, fewer surprises, and dramatically more efficient pathways to approval.

From Expert Judgment to Rule-Based Intelligence

Regulatory prescreening has traditionally relied on the experience and instincts of human evaluators. Those instincts remain essential — but MOSAIQ^TM enhances them through a structured, rule-driven framework that mirrors global agency expectations.

At the core of this evolution is MOSAIQ^TM ’s emerging Rule-Based Regulatory System, designed to:

• Apply consistent “pass/fail” criteria modeled after FDA, EMA, MHRA, Health Canada, and ANVISA guidelines
• Emulate POCA logic to identify confusing similarities early
• Evaluate orthographic, phonetic, and semantic construction risks
• Flag stem conflicts using updated SRC and international stem lists
• Recommend alternative variants or ideation paths when a candidate fails

This isn’t automation for the sake of speed — it’s automation for the sake of accuracy, alignment, and consistency.

Introducing the Regulatory Prompt Library — Expert Logic, Scaled by AI

The next pillar of the MOSAIQ^TM revolution is the Regulatory AI Prompt Library, a curated system of structured prompts designed specifically for safety evaluation across thousands of name candidates.

Built on the STAR framework (Situation, Task, Action, Result), the prompt library gives MOSAIQ^TM the ability to:

• Score names against multiple regulatory dimensions
• Evaluate risk factors using standardized criteria
• Suggest stem-safe variants and compliant naming constructions
• Detect look-alike / sound-alike patterns
• Perform linguistic assessments across key global languages
• Create audit-ready documentation for internal and client use

As this library expands, MOSAIQ^TM becomes increasingly capable of analyzing name safety with the same reasoning patterns used by human regulatory experts — but at unprecedented volume and consistency.

Early Safety Screening: A New Competitive Advantage

When regulatory prescreening is placed at the end of the process, teams often face a frustrating outcome: strong creative candidates fail after significant time and investment.

MOSAIQ^TM eliminates this by embedding regulatory checks directly into the creative workflow.

With MOSAIQ^TM, early prescreening delivers:

• Cleaner list submissions
• Fewer risky names entering rounds
• Significantly reduced attrition before FDA/EMA reviews
• Faster client decision-making
• More strategic control over name construction and direction

This “early intelligence” accelerates timelines and empowers teams to pivot long before regulatory challenges emerge.

The Future: Regulatory Safety That Learns and Adapts

As MOSAIQ^TM continues to evolve, its regulatory capabilities will expand in three powerful new directions:

1. Adaptive Prescreen Formulas

Integrated scoring systems that adjust weighting based on therapeutic class, risk profile, and regional requirements.

2. PRA Libraries for Approvals & Rejections

Databases of historical patterns — including what agencies approve, reject, or require in revisions — informing smarter creative development.

3. Automated Interpretation & Variant Logic

If a name fails for a correctable reason (e.g., stem conflict, problematic construction), MOSAIQTM  will be able to propose safer alternatives instantly.

This is not just technological progress — it’s a change in how regulatory safety works across the entire industry.

Why This Matters for Pharma Brands

Pharmaceutical naming has never been more regulated, more competitive, or more time compressed. MOSAIQ^TM enables teams to meet that challenge with:

• Greater accuracy
• Greater foresight
• Greater efficiency
• Greater confidence

By uniting regulatory logic with AI intelligence and human expertise, MOSAIQ^TM allows Brandsymbol to deliver names that are not just creative — but truly ready for the real world.

This is the Regulatory AI Revolution. And it’s changing what’s possible in pharmaceutical naming.

Continuing the Conversation: Naming Safety in Practice

The evolution of regulatory AI doesn’t stop with technology. It also requires shared understanding across commercial, regulatory, and healthcare teams. That’s why Brandsymbol is launching a monthly webinar series focused on nonproprietary naming, built around the same principles that power MOSAIQ^TM.

Each short, 15-minute session takes a deeper look at a specific aspect of naming safety, development, evaluation, or submission—translating regulatory logic into practical guidance teams can apply long before a name reaches agency review. From stem management and similarity risk to early prescreening strategies, the series is designed to help teams reduce risk earlier and make more confident naming decisions.

For organizations planning USAN or INN submissions in 2026—or looking to strengthen their overall approach to naming safety—the webinar series offers a focused, real-world extension of the regulatory intelligence behind MOSAIQ^TM.